Literature DB >> 21928286

An evidential approach to non-inferiority clinical trials.

Sue-Jane Wang1, Jeffrey D Blume.   

Abstract

We present likelihood methods for defining the non-inferiority margin and measuring the strength of evidence in non-inferiority trials using the 'fixed-margin' framework. Likelihood methods are used to (1) evaluate and combine the evidence from historical trials to define the non-inferiority margin, (2) assess and report the smallest non-inferiority margin supported by the data, and (3) assess potential violations of the constancy assumption. Data from six aspirin-controlled trials for acute coronary syndrome and data from an active-controlled trial for acute coronary syndrome, Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) trial, are used for illustration. The likelihood framework offers important theoretical and practical advantages when measuring the strength of evidence in non-inferiority trials. Besides eliminating the influence of sample spaces and prior probabilities on the 'strength of evidence in the data', the likelihood approach maintains good frequentist properties. Violations of the constancy assumption can be assessed in the likelihood framework when it is appropriate to assume a unifying regression model for trial data and a constant control effect including a control rate parameter and a placebo rate parameter across historical placebo controlled trials and the non-inferiority trial. In situations where the statistical non-inferiority margin is data driven, lower likelihood support interval limits provide plausibly conservative candidate margins.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21928286     DOI: 10.1002/pst.513

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  Simultaneous control of error rates in fMRI data analysis.

Authors:  Hakmook Kang; Jeffrey Blume; Hernando Ombao; David Badre
Journal:  Neuroimage       Date:  2015-08-10       Impact factor: 6.556

2.  Likelihood approach for evaluating bioequivalence of highly variable drugs.

Authors:  Liping Du; Leena Choi
Journal:  Pharm Stat       Date:  2014-11-19       Impact factor: 1.894

Review 3.  The evidential statistical paradigm in genetics.

Authors:  Lisa J Strug
Journal:  Genet Epidemiol       Date:  2018-08-18       Impact factor: 2.135

4.  Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.

Authors:  Wesley H Self; Thomas G Stewart; Allison P Wheeler; Wissam El Atrouni; Amanda J Bistran-Hall; Jonathan D Casey; Vince D Cataldo; James D Chappell; Claudia S Cohn; Jessica B Collins; Mark R Denison; Marjolein de Wit; Sheri L Dixon; Abhijit Duggal; Terri L Edwards; Magali J Fontaine; Adit A Ginde; Michelle S Harkins; Thelma Harrington; Estelle S Harris; Daanish Hoda; Tina S Ipe; Stuti J Jaiswal; Nicholas J Johnson; Alan E Jones; Maryrose Laguio-Vila; Christopher J Lindsell; Jason Mallada; Manoj J Mammen; Ryan A Metcalf; Elizabeth A Middleton; Simon Mucha; Hollis R O'Neal; Sonal R Pannu; Jill M Pulley; Xian Qiao; Jay S Raval; Jillian P Rhoads; Harry Schrager; Carl Shanholtz; Nathan I Shapiro; Stephen J Schrantz; Isaac Thomsen; Krista K Vermillion; Gordon R Bernard; Todd W Rice
Journal:  Trials       Date:  2021-03-20       Impact factor: 2.279

5.  Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.

Authors:  Wesley H Self; Thomas G Stewart; Allison P Wheeler; Wissam El Atrouni; Amanda J Bistran-Hall; Jonathan D Casey; Vince D Cataldo; James D Chappell; Claudia S Cohn; Jessica B Collins; Mark R Denison; Marjolein de Wit; Sheri L Dixon; Abhijit Duggal; Terri L Edwards; Magali J Fontaine; Adit A Ginde; Michelle S Harkins; Thelma Harrington; Estelle S Harris; Daanish Hoda; Tina S Ipe; Stuti J Jaiswal; Nicholas J Johnson; Alan E Jones; Maryrose Laguio-Vila; Christopher J Lindsell; Jason Mallada; Manoj J Mammen; Ryan A Metcalf; Elizabeth A Middleton; Simon Mucha; Hollis R O'Neal; Sonal R Pannu; Jill M Pulley; Xian Qiao; Jay S Raval; Jillian P Rhoads; Harry Schrager; Carl Shanholtz; Nathan I Shapiro; Stephen J Schrantz; Isaac Thomsen; Krista K Vermillion; Gordon R Bernard; Todd W Rice
Journal:  Res Sq       Date:  2021-03-02

6.  Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.

Authors:  Wesley H Self; Allison P Wheeler; Thomas G Stewart; Harry Schrager; Jason Mallada; Christopher B Thomas; Vince D Cataldo; Hollis R O'Neal; Nathan I Shapiro; Conor Higgins; Adit A Ginde; Lakshmi Chauhan; Nicholas J Johnson; Daniel J Henning; Stuti J Jaiswal; Manoj J Mammen; Estelle S Harris; Sonal R Pannu; Maryrose Laguio-Vila; Wissam El Atrouni; Marjolein de Wit; Daanish Hoda; Claudia S Cohn; Carla McWilliams; Carl Shanholtz; Alan E Jones; Jay S Raval; Simon Mucha; Tina S Ipe; Xian Qiao; Stephen J Schrantz; Aarthi Shenoy; Richard D Fremont; Eric J Brady; Robert H Carnahan; James D Chappell; James E Crowe; Mark R Denison; Pavlo Gilchuk; Laura J Stevens; Rachel E Sutton; Isaac Thomsen; Sandra M Yoder; Amanda J Bistran-Hall; Jonathan D Casey; Christopher J Lindsell; Li Wang; Jill M Pulley; Jillian P Rhoads; Gordon R Bernard; Todd W Rice
Journal:  Chest       Date:  2022-07-01       Impact factor: 10.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.